Inés Modrego Pardo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Inés Modrego Pardo has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
Carlos Morillas Ariño
Servicio de Endocrinología y Nutrición, Unidad de Identidad de Género, Hospital Universitario Dr. Peset, Valencia, Spain
4 shared publicationsFelipe Hurtado Murillo
Centro de Salud Sexual y Reproductiva, Unidad de Identidad de Género, Centro de Salud Arabista Ambrosio Huici, Valencia, Spain
4 shared publicationsMarcelino Gómez Balaguer
Servicio de Endocrinología y Nutrición, Unidad de Identidad de Género, Hospital Universitario Dr. Peset, Valencia, España
4 shared publications- Oscar Moreno-Perez
Dr. Balmis University General Hospital Alicante Spain
4 shared publications - Rebeca Reyes-García
Unidad de Endocrinología, Hospital Universitario Torrecárdenas, Almería, Spain
4 shared publications - Cristina Guillen-Morote
Department of Endocrinology and Nutrition, General University Hospital Dr. Balmis of Alicante, Institute of Health and Biomedical Research of Alicante (ISABIAL), 03010 Alicante, Spain
3 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (9) , 1369-1384
Insulin Injection Behaviors and Association with Glycemic Outcomes in Patients with Diabetes: A Real-World Survey in Spain
- 28 July 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (9) , 1369-1384
Open AccessInsulin Injection Behaviors and Association with Glycemic Outcomes in Patients with Diabetes: A Real-World Survey in Spain
- Open Access
Clinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy)
Background: Sex differences in type 2 diabetes (T2D) are a growing area of diabetes research. No data have been reported on sex differences with oral semaglutide (oSEMA) in a real-world setting. Methods: We included people with T2D who started treatment with oSEMA in routine clinical practice between November 2021 and November 2022, with at least one report of clinical follow-up (FU) data at 3 months. We evaluated in women with T2D (WWT2D) the clinical effectiveness of oSEMA and factors associated with clinical response and persistence. We also analyzed differences in baseline characteristics, clinical effectiveness, persistence rates and safety according to biological sex. Results: Of the 1018 subjects [median age: 63 years, body mass index (BMI): 33.8 kg/m2, HbA1c: 7.8%], 469 were WWT2D. In WWT2D, oSEMA reduced HbA1c by 0.7% [−0.1 to −1.3] and 0.9% [−0.2 to −1.5] at the 6- and 12-month FU visits, while weight decreased by 4.6% [2.0 to 7.9] and 7.2% [2.5 to 10.9], respectively. Weight loss was >10% in 29.8% of WWT2D (95% CI 25.8 to 34.1); meanwhile, the combined endpoint (HbA1c decrease ≥ 1% + weight reduction ≥ 5%) was achieved in 23.5% (95% CI 19.8 to 27.5%) of WWT2D at the 12-month FU visit. Achievement of glycaemic targets was similar in women and men (59.3% vs. 61.1%). We found no sex differences in weight loss (6.9% vs. 6.8%), oSEMA maintenance dose, persistence rate (76.3% vs. 77.3%), or adverse events. Conclusions: oSEMA was effective and safe in WWT2D in a real-world setting, with nearly one-third of patients reporting weight loss >10% and more than two-thirds achieving HbA1c < 7%. oSEMA showed no sex bias in terms of effectiveness and safety.
Open AccessClinical Effectiveness of Oral Semaglutide in Women with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Women_ENDO2S-RWD Substudy)
Background: Sex differences in type 2 diabetes (T2D) are a growing area of diabetes research. No data have been reported on sex differences with oral semaglutide (oSEMA) in a real-world setting. Methods: We included people with T2D who started treatment with oSEMA in routine clinical practice between November 2021 and November 2022, with at least one report of clinical follow-up (FU) data at 3 months. We evaluated in women with T2D (WWT2D) the clinical effectiveness of oSEMA and factors associated with clinical response and persistence. We also analyzed differences in baseline characteristics, clinical effectiveness, persistence rates and safety according to biological sex. Results: Of the 1018 subjects [median age: 63 years, body mass index (BMI): 33.8 kg/m2, HbA1c: 7.8%], 469 were WWT2D. In WWT2D, oSEMA reduced HbA1c by 0.7% [−0.1 to −1.3] and 0.9% [−0.2 to −1.5] at the 6- and 12-month FU visits, while weight decreased by 4.6% [2.0 to 7.9] and 7.2% [2.5 to 10.9], respectively. Weight loss was >10% in 29.8% of WWT2D (95% CI 25.8 to 34.1); meanwhile, the combined endpoint (HbA1c decrease ≥ 1% + weight reduction ≥ 5%) was achieved in 23.5% (95% CI 19.8 to 27.5%) of WWT2D at the 12-month FU visit. Achievement of glycaemic targets was similar in women and men (59.3% vs. 61.1%). We found no sex differences in weight loss (6.9% vs. 6.8%), oSEMA maintenance dose, persistence rate (76.3% vs. 77.3%), or adverse events. Conclusions: oSEMA was effective and safe in WWT2D in a real-world setting, with nearly one-third of patients reporting weight loss >10% and more than two-thirds achieving HbA1c < 7%. oSEMA showed no sex bias in terms of effectiveness and safety.
- Open Access
- 11 July 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (8) , sfaf227
Effects of Oral Semaglutide on Kidney Outcomes in People with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Renal_ENDO2S-RWD substudy)
Background: Subcutaneous semaglutide has shown kidney-protective effects in people with type 2 diabetes (PWT2D), but data on oral semaglutide remain limited. This multicenter real-world study evaluates the clinical effectiveness of oral semaglutide on kidney outcomes in PWT2D. Methods: We included PW2TD aged ≥18 years who initiated oral semaglutide in routine practice between 2021 and 2022 in the Spanish National Health System, with at least one report of clinical follow-up (FU) data at 3 months. Co-primary endpoints were changes in urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) slope at 6-12 months. We also assessed baseline predictors of response, drug persistence, and safety by CKD severity. Results: Data were available for 819 PWT2D (median age 63 years, eGFR 88.1mL/min/1.73m2, UACR 12 mg/g, 45.8% female), median FU was 8.96 months. Oral semaglutide reduced UACR by 30.3% and 40.0% in the overall cohort, by 40.2% and 50.7% in those with a UACR ≥ 30 mg/g, and by 40.6% and 49.9% in those with a UACR ≥ 300 mg/g at 6 and 12-months FU, respectively. PWT2D with a low age-adjusted risk of liver fibrosis by the FIB-4 index had increased odds of achieving a >30% reduction in UACR (aOR 5.50 [95%CI 1.6-18.7]) regardless of baseline background. Metabolic and weight loss effectiveness, safety and persistence of oral semaglutide were consistent across CKD severities. Conclusions: In a real-world setting, oral semaglutide treatment for up to 52 weeks resulted in clinically meaningful reductions in albuminuria without changes in eGFR slope in PWT2D. Effectiveness, safety and tolerability were not influenced by CKD severity.
- 11 July 2025
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 18 (8) , sfaf227
Open AccessEffects of Oral Semaglutide on Kidney Outcomes in People with Type 2 Diabetes: A Nationwide, Multicentre, Retrospective, Observational Study (Renal_ENDO2S-RWD substudy)
Background: Subcutaneous semaglutide has shown kidney-protective effects in people with type 2 diabetes (PWT2D), but data on oral semaglutide remain limited. This multicenter real-world study evaluates the clinical effectiveness of oral semaglutide on kidney outcomes in PWT2D. Methods: We included PW2TD aged ≥18 years who initiated oral semaglutide in routine practice between 2021 and 2022 in the Spanish National Health System, with at least one report of clinical follow-up (FU) data at 3 months. Co-primary endpoints were changes in urinary albumin to creatinine ratio (UACR) and estimated glomerular filtration rate (eGFR) slope at 6-12 months. We also assessed baseline predictors of response, drug persistence, and safety by CKD severity. Results: Data were available for 819 PWT2D (median age 63 years, eGFR 88.1mL/min/1.73m2, UACR 12 mg/g, 45.8% female), median FU was 8.96 months. Oral semaglutide reduced UACR by 30.3% and 40.0% in the overall cohort, by 40.2% and 50.7% in those with a UACR ≥ 30 mg/g, and by 40.6% and 49.9% in those with a UACR ≥ 300 mg/g at 6 and 12-months FU, respectively. PWT2D with a low age-adjusted risk of liver fibrosis by the FIB-4 index had increased odds of achieving a >30% reduction in UACR (aOR 5.50 [95%CI 1.6-18.7]) regardless of baseline background. Metabolic and weight loss effectiveness, safety and persistence of oral semaglutide were consistent across CKD severities. Conclusions: In a real-world setting, oral semaglutide treatment for up to 52 weeks resulted in clinically meaningful reductions in albuminuria without changes in eGFR slope in PWT2D. Effectiveness, safety and tolerability were not influenced by CKD severity.
- Open Access
- 21 February 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (4) , sfae039
Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease?
We are entering a new era in the management of adiposity-based chronic disease (ABCD) with type 2 diabetes (T2D) and related chronic kidney disease (CKD). ABCD, T2D and CKD can affect almost every major organ system and have a particularly strong impact on the incidence of cardiovascular disease (CVD) and heart failure. ABCD and the associated insulin resistance are at the root of many cardiovascular, renal and metabolic (CKM) disorders, thus an integrated therapeutic framework using weight loss (WL) as a disease-modifying intervention could simplify the therapeutic approach at different stages across the lifespan. The breakthrough of highly effective WL drugs makes achieving a WL of >10% possible, which is required for a potential T2D disease remission as well as for prevention of microvascular disease, CKD, CVD events and overall mortality. The aim of this review is to discuss the link between adiposity and CKM conditions as well as placing weight management at the centre of the holistic CKM syndrome approach with a focus on CKD. We propose the clinical translation of the available evidence into a transformative Dysfunctional Adipose Tissue Approach (DATA) for people living with ABCD, T2D and CKD. This model is based on the interplay of four essential elements (i.e. adipocentric approach and target organ protection, dysfunctional adiposity, glucose homeostasis, and lifestyle intervention and de-prescription) together with a multidisciplinary person-centred care. DATA could facilitate decision-making for all clinicians involved in the management of these individuals, and if we do this in a multidisciplinary way, we are prepared to meet the adipocentric challenge.
- 21 February 2024
- Published by Oxford University Press (OUP) in Clinical Kidney Journal
- Vol. 17 (4) , sfae039
Open AccessAre we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease?
We are entering a new era in the management of adiposity-based chronic disease (ABCD) with type 2 diabetes (T2D) and related chronic kidney disease (CKD). ABCD, T2D and CKD can affect almost every major organ system and have a particularly strong impact on the incidence of cardiovascular disease (CVD) and heart failure. ABCD and the associated insulin resistance are at the root of many cardiovascular, renal and metabolic (CKM) disorders, thus an integrated therapeutic framework using weight loss (WL) as a disease-modifying intervention could simplify the therapeutic approach at different stages across the lifespan. The breakthrough of highly effective WL drugs makes achieving a WL of >10% possible, which is required for a potential T2D disease remission as well as for prevention of microvascular disease, CKD, CVD events and overall mortality. The aim of this review is to discuss the link between adiposity and CKM conditions as well as placing weight management at the centre of the holistic CKM syndrome approach with a focus on CKD. We propose the clinical translation of the available evidence into a transformative Dysfunctional Adipose Tissue Approach (DATA) for people living with ABCD, T2D and CKD. This model is based on the interplay of four essential elements (i.e. adipocentric approach and target organ protection, dysfunctional adiposity, glucose homeostasis, and lifestyle intervention and de-prescription) together with a multidisciplinary person-centred care. DATA could facilitate decision-making for all clinicians involved in the management of these individuals, and if we do this in a multidisciplinary way, we are prepared to meet the adipocentric challenge.
- Open Access
- 27 December 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (4) , 1519-1523
Real‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study ( ENDO 2 S‐RWD )
- 27 December 2023
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 26 (4) , 1519-1523
Open AccessReal‐world effectiveness and safety of oral semaglutide in people living with type 2 diabetes: A nationwide multicentre retrospective observational study ( ENDO 2 S‐RWD )
- 1 August 2020
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 67 (7) , 431-437
Tendencia de la población española de búsqueda en internet sobre información relacionada con diferentes dietas
- 1 August 2020
- Published by Elsevier in Endocrinología, Diabetes y Nutrición
- Vol. 67 (7) , 431-437
Tendencia de la población española de búsqueda en internet sobre información relacionada con diferentes dietas